Combining Mesenchymal Stem Cells Derived from Wharton's Jelly and Amniotic Biomaterial Scaffolds for Cell Delivery.
Umamagesh PalaniappanJaianand KannaiyanBalaji PaulrajPonmurugan KaruppiahSanthosh BasavarajappaAsad SyedAbdallah M ElgorbanNouf S ZaghloulVeeramanikandan VeeramaniPublished in: ACS omega (2023)
Therapies based on mesenchymal stem cells have incredible potential for tissue regeneration. Tracking cells and keeping them at the injury site are creating challenges. The cells can be sown into a biocompatible scaffold as a possible remedy. Tissue engineering construction is a difficult, multistep process that requires many variables to be optimized, including the stem cell source, molecular components, scaffold architecture, and a suitable in vivo animal model. In order to locate a suitable regenerative scaffold for delivering stromal cells to regions with greater healing potential, we assessed whether human Wharton's Jelly-derived mesenchymal stem cells (WJMSCs) responded on biological membranes. WJMSCs were isolated, characterized, and seeded onto an amniotic membrane-based scaffold. Results obtained in vitro revealed that the seeded scaffolds had a significant impact on a number of critical variables, including seeding effectiveness, cellular dispersion, adhesion, survival, and metabolic activity. The research sheds light on a fresh facet of material behavior and paves the way for the creation of scaffold materials that support tissue regeneration and repair. Furthermore, the methods used herein can be utilized to test other scaffold materials to increase their healing potential with WJMSCs.
Keyphrases
- tissue engineering
- umbilical cord
- mesenchymal stem cells
- stem cells
- induced apoptosis
- cell therapy
- cell cycle arrest
- single cell
- endothelial cells
- systematic review
- bone marrow
- human health
- staphylococcus aureus
- escherichia coli
- cell death
- signaling pathway
- cystic fibrosis
- wound healing
- endoplasmic reticulum stress
- drug delivery